Bayer Japan Unit Sells iPS Cell Technology Patents To Izumi Of U.S.
This article was originally published in PharmAsia News
Executive Summary
Japan's Bayer Yakuhin says its parent company plans to sell patents it holds on its induced pluripotent stem cells to a U.S. bioventure, iZumi Bio. The technology patents are based on the cell line technology invented by a Japanese researcher, now a researcher at iZumi. The sale by Bayer Yakuhin, a subsidiary of German drug maker Bayer AG, includes both domestic and international patents for the technology. The price was not disclosed. (Click here for more - a subscription may be required
You may also be interested in...
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.